ISSN 1662-4009 (online)

Volume 15 | ESPEYB15 | Next issue

Yearbook of Paediatric Endocrinology 2018

4 Growth and Growth Factors

Important for clinical practice

ey0015.4-1 | Important for clinical practice | ESPEYB15

4.1 Growth hormone treatment in children with Prader-Willi syndrome: three years of longitudinal data in prepubertal children and adult height data from the KIGS database

NE Bakker , A Lindberg , J Heissler , HA Wollmann , C Camacho-Hübner , AC Hokken-Koelega , on behalf of the KIGS Steering Committee

To read the full abstract: J Clin Endocrinol Metab 2017; 102:1702-1711Short stature is a common feature of children with Prader-Willi syndrome (PWS) as well as hypotonia, hyperphagia, obesity, hypogonadism, behavioral disturbances and hypothalamic dysfunction. Alterations in the GH/IGF1 axis are common in patients with PWS, GH deficiency occurring in approximately 74% and IGF-1...

ey0015.4-2 | Important for clinical practice | ESPEYB15

4.2 Efficacy of growth hormone treatment in children with type 1 diabetes mellitus and growth hormone deficiency-an analysis of KIGS data

W Bonfig , A Lindberg , M Carlsson , W Cutfield , D Dunger , C Camacho-Hübner , RW Holl

To read the full abstract: J Pediatr 2018; 198: 260-264The incidence of T1DM in children <15 years is increasing at an overall annual relative rate of 3.9% (95% CI 3.6-4.2) [11]. The prevalence of GHD is estimated at approximately 1:4000 to 1:10000 [12-14]. Management of the very rare patients who have both T1DM and GHD raises questions of efficacy and safety of ...

ey0015.4-3 | Important for clinical practice | ESPEYB15

4.3 Cardiovascular risk factors and carotid intima media thickness in young adults born small for gestational age after cessation of growth hormone treatment: a 5-year longitudinal study

M van der Steen , GF Kerkhof , CCJ Smeets , ACS Hokken-Koelega

To read the full abstract: Lancet Diabetes Endocrinol 2017;5:975-985Whereas most SGA children experience spontaneous catch-up growth leading to the achievement of normal adult height, approximately 10% remain short and are candidates for GH therapy. SGA subjects have increased cardio-metabolic disease risk [17] and the effects of GH treatment on blood...

ey0015.4-4 | Important for clinical practice | ESPEYB15

4.4 Consensus Based Definition of Growth Restriction in the Newborn

IM Beune , FH Bloomfield , W Ganzevoort , ND Embleton , PJ Rozance , AG van Wassenaer-Leemhuis , K Wynia , SJ Gordijn

To read the full abstract: J Pediatr 2018. 196:71-76Fetal growth restriction describes a fetus who fails to achieve their biological growth potential, remaining smaller than its genetic potential, and occurs in ~10% of pregnancies [22]. FGR and SGA are terms that are often and wrongly used in an interchangeable way. SGA does not inevitably entail a pathological condition, b...

ey0015.4-5 | Important for clinical practice | ESPEYB15

4.5 Growth hormone improves cardiopulmonary capacity and body composition in children with growth hormone deficiency

D Capalbo , F Barbieri , N Improda , F Giallauria , E Di Pietro , A Rapacciuolo , R Di Mase , C Vigorito , M Salerno

To read the full abstract: J Clin Endocrinol Metab 2017; 102(11):4080-4088GH influences the structure and function of the heart. Untreated GHD adults have a worse cardiometabolic disease risk profile characterized by altered body composition, unfavorable changes in metabolism, reduced left ventricular mass and cardiac output and decreased exercise capacity [25-26]. GH...